Cargando…

Nonmyeloablative Allogeneic Stem-Cell Transplantation for Metastatic Renal Cell Cancer: A Review and Update

Metastatic renal cell carcinoma (RCC) is resistant to conventional chemotherapy and radiotherapy. However, immunotherapy appears to be effective in 15—20% of cases, with interleukin-2 becoming the standard therapy for this disease. As a consequence of the immune susceptibility of RCC, other avenues...

Descripción completa

Detalles Bibliográficos
Autores principales:	Erotocritou, P., Ahmed, H., Patel, S.S., Shergill, I., Patel, H.R., Shah, P.M., Arya, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	TheScientificWorldJOURNAL 2006
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917236/ https://www.ncbi.nlm.nih.gov/pubmed/17619726 http://dx.doi.org/10.1100/tsw.2006.391

Ejemplares similares

Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer
por: Banna, G L, et al.
Publicado: (2006)

What Role Is There for Antithymocyte Globulin in Allogeneic Nonmyeloablative Canine Hematopoietic Cell Transplantation?
por: Diaconescu, Razvan, et al.
Publicado: (2005)

Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation
por: Toh, H C, et al.
Publicado: (2011)

Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation
por: Kanda, Junya, et al.
Publicado: (2011)

Graft-versus-Leukemia Effect of Nonmyeloablative Stem Cell Transplantation
por: Imamura, Masahiro, et al.
Publicado: (2009)

Kinetics of IL-7 and IL-15 Levels after Allogeneic Peripheral Blood Stem Cell Transplantation following Nonmyeloablative Conditioning
por: De Bock, Muriel, et al.
Publicado: (2013)

Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
por: Walter, Roland B., et al.
Publicado: (2014)

Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT
por: van der Velden, Walter J. F. M., et al.
Publicado: (2021)

(GT)(n) Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
por: Køllgaard, Tania, et al.
Publicado: (2016)

High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation
por: Long-Boyle, Janel R, et al.
Publicado: (2010)

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide
por: Munchel, Ashley, et al.
Publicado: (2011)

Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin
por: Veltri, Lauren, et al.
Publicado: (2013)

Immune Reconstitution Kinetics following Intentionally Induced Mixed Chimerism by Nonmyeloablative Transplantation
por: Kim, Nayoun, et al.
Publicado: (2015)

High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients
por: Jaklič, Alenka, et al.
Publicado: (2013)

Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC)
por: Bregni, Marco, et al.
Publicado: (2011)

Autologous nonmyeloablative hematopoietic stem cell transplantion in newly diagnosed childhood type 1 diabetes mellitus: the first year report
por: Luo, Feihong, et al.
Publicado: (2013)

Clinical Allogeneic and Autologous Islet Cell Transplantation: Update
por: Matsumoto, Shinichi
Publicado: (2011)

Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioning
por: Schwaiger, Elisabeth, et al.
Publicado: (2012)

A nonmyeloablative chimeric mouse model accurately defines microglia and macrophage contribution in glioma
por: Yu, K., et al.
Publicado: (2018)

Microvascular Complications in Type 1 Diabetes: A Comparative Analysis of Patients Treated with Autologous Nonmyeloablative Hematopoietic Stem-Cell Transplantation and Conventional Medical Therapy
por: Penaforte-Saboia, Jaquellyne G., et al.
Publicado: (2017)

Peripheral T-cell Lymphomas: Updates in Allogeneic Hematopoietic Stem Cell Transplantation
por: Huang, Wen-Rong, et al.
Publicado: (2018)

Allogeneic bone marrow transplantation can suppress established and otherwise chronic collagen-induced arthritis after a nonmyeloablative conditioning regimen employing anti-CD40 ligand monoclonal antibody
por: Flierman, R, et al.
Publicado: (2004)

Idiopathic Pneumonia Syndrome and Thrombotic Microangiopathy Following Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation and Posttransplant Cyclophosphamide: A Case Report
por: Liu, Wei-Hsin, et al.
Publicado: (2015)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update
por: Bilgin, Yavuz M
Publicado: (2021)

Small Split Doses of CD34(+) Peripheral Blood Stem Cells to Support Repeated Cycles of Nonmyeloablative Chemotherapy
por: Yankelevich, Maxim, et al.
Publicado: (2017)

Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease
por: Paplham, Pamela, et al.
Publicado: (2014)

Extension of Maximal Lifespan and High Bone Marrow Chimerism After Nonmyeloablative Syngeneic Transplantation of Bone Marrow From Young to Old Mice
por: Kovina, Marina V., et al.
Publicado: (2019)

A Review of Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Breast Cancer
por: Karadurmus, Nuri, et al.
Publicado: (2018)

Allogenic Hematopoietic Stem Cell Transplantation in Pemphigus Vulgaris: A Single-Center Experience
por: Vanikar, Aruna V, et al.
Publicado: (2012)

Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update
por: Mohty, B, et al.
Publicado: (2011)

Targeted therapy for metastatic renal cell carcinoma
por: Patel, P H, et al.
Publicado: (2006)

Intestinal dysbiosis and allogeneic hematopoietic progenitor cell transplantation
por: Raghunathan, Vikram M., et al.
Publicado: (2016)

Infections in Allogeneic Stem Cell Transplantation
por: Pereira, Marcus R., et al.
Publicado: (2018)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update [Corrigendum]
Publicado: (2022)

Human metapneumovirus infection after allogeneic hematopoietic stem cell transplantation
por: Egli, A., et al.
Publicado: (2012)

Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients
por: Yew, P Y, et al.
Publicado: (2015)

Transmission of lupus anticoagulant by allogeneic stem cell transplantation
por: Massoud, Mira Romany, et al.
Publicado: (2014)

Blockade of TNFα to Improve Human CD34+ Cell Repopulating Activity in Allogeneic Stem Cell Transplantation
por: Senyuk, Vitalyi, et al.
Publicado: (2019)

Regulatory T Cells in Allogeneic Stem Cell Transplantation
por: Michael, Maria, et al.
Publicado: (2013)

Cytomegalovirus monitoring in allogeneic haemopoietic stem cell transplant recipients
por: Ramalingam, S., et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_6ptuq1s77h2vaq2movmsnajlh7